| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors |
| 24 Sep 2026 |
Form 4: Czibere Akos, Chief Medical Officer
Received 12,500 shares by exercise or conversion ($61.9K) · Sold 12,500 shares ($259K) |
| 23 Sep 2026 | 144 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors |
| 21 Jul 2026 |
Form 4: Herrmann Ken, Director
Received 4,856 shares by exercise or conversion ($2.86K) · Sold 4,856 shares ($119K) |
| 20 Jul 2026 |
Form 4: Herrmann Ken, Director
Received 3,065 shares by exercise or conversion ($245) · Sold 3,065 shares ($77.3K) |
| 20 Jul 2026 | 144 |
| 17 Jul 2026 | 144 |
| 10 Jul 2026 |
Form 4: Ron-Bigger Shulamit, Chief Operating Officer
Received 50,000 shares by exercise or conversion ($183K) · Sold 50,000 shares ($1.39M) |
| 10 Jul 2026 |
Form 4: Czibere Akos, Chief Medical Officer
Received 50,000 shares by exercise or conversion ($248K) · Sold 50,000 shares ($1.39M) |
| 08 Jul 2026 | 144 |
| 08 Jul 2026 | 144 |
| 14 May 2026 | SCHEDULE 13G |
| 11 May 2026 | 10-Q |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments |
| 16 Apr 2026 |
Form 4: Gormley Glenn, Director
Granted 37,866 Stock Option (Right to Buy) |
| 16 Apr 2026 |
Form 3: Gormley Glenn, Director
No securities owned |
Loading...